Innovation Week: pushing the boundaries of AI in drug discovery

“Innovation week is about challenging and shaping the future. It’s about pushing the boundaries of AI, biology, precision medicine, data science and chemistry to develop better treatments for the patients who need them.”

At BenevolentAI, our work sits at the convergence of some of the most important trends of our time. But delivering life changing technology at pace is no easy task, especially as technology advancements accelerate faster than ever. So in this fast-moving world, we at BenevolentAI aim to ensure that while delivering on our ambitious objectives, we also support approaches to innovation that can unlock new opportunities and future growth.

Innovation Week aims to tackle this challenge, the Benevolent way. We gathered our entire team together in London to collaborate on projects and challenges that have the potential to transform our work and take it to the next level. We asked our CEO, CTO and our team to tell us about how the week played out:

Daniel Neil CTO BenevolentAI Talking about Innovation Week

Fueling continuous innovation at BenevolentAI

BenevolentAI’s CTO, Daniel Neil, discusses four approaches we use to fuel continuous innovation, including setting the criteria for success, making it okay to fail and enabling innovation at the intersections.

Read our blog →

More Posts

You Might Also Like

Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022